Intervention

Valsartan

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 82 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials82
Recruiting4
Common conditions25
Lead sponsors shown15
Advertisement

Clinical trials

60 shown
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and WarfarinNCT07331389 · 2025-09-24
RECRUITING
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202ANCT06643819 · 2024-10-14
RECRUITING
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/ValsartanNCT05194111 · 2022-08-11
RECRUITING
Bariatric Surgery and Pharmacokinetics of ValsartanNCT03535376 · 2016-11-02
RECRUITING
Sacubitril/Valsartan Versus Valsartan Alone on Left Atrial Volume Index in Hypertensive PatientsNCT07853625 · 2026-10-01
NOT_YET_RECRUITING
TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin TherapyNCT07139405 · 2026-09-01
NOT_YET_RECRUITING
Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection FractionNCT06536309 · 2026-08-27
WITHDRAWN
A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive PatientsNCT06771245 · 2025-01-24
NOT_YET_RECRUITING
Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic NephropathyNCT06501651 · 2024-08-01
UNKNOWN
Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial FibrillationNCT05528419 · 2023-02-06
COMPLETED
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential HypertensionNCT05359068 · 2021-06-10
COMPLETED
Sacubitril/Valsartan Versus Valsartan in Heart Failure With Improved Ejection FractionNCT04803175 · 2021-03-16
UNKNOWN
Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With HypertensionNCT04800081 · 2020-07-09
UNKNOWN
The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart FailureNCT04688294 · 2020-01-01
COMPLETED
LCZ696 in Advanced LV Hypertrophy and HFpEFNCT03928158 · 2019-05-31
COMPLETED
Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 DiabetesNCT03893526 · 2019-01-25
COMPLETED
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1NCT03738878 · 2018-11-15
TERMINATED
Nighttime Valsartan in Hemodialysis HypertensionNCT03594825 · 2018-11-01
UNKNOWN
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MINCT03552575 · 2018-07-01
COMPLETED
Sacubitril-valsartan Versus Usual Anti-hypertensives in LVADNCT03279861 · 2017-11-01
WITHDRAWN
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF PatientsNCT03066804 · 2017-08-22
COMPLETED
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MINCT02924727 · 2016-12-09
COMPLETED
Amlodipine Versus Valsartan for Improvement of Diastolic Dysfunction Associated With HypertensionNCT02973035 · 2016-12-01
COMPLETED
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection FractionNCT02884206 · 2016-11-23
COMPLETED
The DDI Study of SP2086 and ValsartanNCT02817217 · 2016-03-01
UNKNOWN
Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvationNCT04687111 · 2015-12-16
UNKNOWN
Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With HypertensionNCT02480764 · 2015-08-27
COMPLETED
Fimasartan Achieving SBP Target (FAST) StudyNCT02495324 · 2015-06-01
COMPLETED
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection FractionNCT01920711 · 2014-07-18
COMPLETED
A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential HypertensionNCT01878201 · 2013-05-01
COMPLETED
The Drug-drug Interaction of SP2086 and ValsartanNCT02815657 · 2013-04-01
COMPLETED
24 Hour Ambulatory Cardiac Oxygen ConsumptionNCT05170061 · 2013-02-01
COMPLETED
Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive HypertensionNCT01681576 · 2012-08-01
COMPLETED
New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure LoweringNCT01609959 · 2012-06-01
COMPLETED
A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential HypertensionNCT01672476 · 2012-04-01
COMPLETED
Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.NCT01541189 · 2012-02-01
COMPLETED
Safety and Tolerability of Valsartan in Children 6 to 17 Years of AgeNCT01365481 · 2011-08-01
COMPLETED
Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy VolunteersNCT01353508 · 2011-03-01
COMPLETED
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic HypertensionNCT01281306 · 2011-01-01
COMPLETED
FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)NCT01071122 · 2010-01-01
COMPLETED
LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection FractionNCT00887588 · 2009-11-01
COMPLETED
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney DiseaseNCT01129557 · 2009-09-01
TERMINATED
Valsartan Intensified Primary Care Reduction of Blood Pressure StudyNCT00902304 · 2009-07-01
COMPLETED
To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan AloneNCT01070043 · 2009-06-01
COMPLETED
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes MellitusNCT00927394 · 2009-05-01
COMPLETED
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During ExerciseNCT00819767 · 2009-02-01
COMPLETED
8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 HypertensionNCT00809926 · 2009-01-01
COMPLETED
Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes NephropathyNCT00655330 · 2008-05-01
UNKNOWN
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.NCT00698646 · 2008-04-01
COMPLETED
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.NCT00696436 · 2008-04-01
COMPLETED
Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to LisinoprilNCT00657241 · 2008-04-01
COMPLETED
The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With HypertensionNCT00921570 · 2008-02-01
COMPLETED
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential HypertensionNCT00591578 · 2007-12-01
COMPLETED
Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a DayNCT00700271 · 2007-10-01
COMPLETED
Efficacy and Safety of LCZ696A in Patients With Essential HypertensionNCT00549770 · 2007-09-01
COMPLETED
Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With HypertensionNCT00446511 · 2007-06-01
COMPLETED
Preventing Microalbuminuria in Type 2 DiabetesNCT00503152 · 2007-05-01
COMPLETED
Preventing ESRD in Overt Nephropathy of Type 2 DiabetesNCT00494715 · 2007-05-01
COMPLETED
A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With HypertensionNCT00457626 · 2007-04-09
COMPLETED
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular HypertrophyNCT00446563 · 2007-03-01
COMPLETED

Common conditions

Hypertension44Essential Hypertension6Heart Failure5Diabetes3Heart Failure With Preserved Ejection Fraction3Type 2 Diabetes3Type 2 Diabetes Mellitus3Congestive Heart Failure2Diabetic Nephropathy2Healthy2Left Ventricular Diastolic Dysfunction2Nephropathy2Acute Myocardial Infarction1Albuminuria1Atrial Arrhythmia1Atrial Fibrillation Recurrent1Atrial Remodeling1Cardiovascular Morbidity1Chronic Heart Failure1Chronic Heart Failure (CHF)1Chronic Kidney Disease1Coronary Artery Disease1Diabetes Mellitus1Diabetic Nephropathies1Diastolic Dysfunction1

Trial status mix

COMPLETED60
UNKNOWN9
RECRUITING4
NOT_YET_RECRUITING3
TERMINATED3
WITHDRAWN3

Phase mix

PHASE433
PHASE327
PHASE211
PHASE16
NA4
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.